The table below is a review of notable updates that occurred in March 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The burden of alcohol-related cirrhosis (AC) among women has decreased but is disproportionately high in lower Sociodemographic Index (SDI) regions.

Your patient with SSc and pulmonary arterial hypertension (PAH) is undergoing evaluation prior to initiation of oral riociguat. Creatinine clearance is 10 mL/min. What is the most appropriate starting ...

In a best practice guideline, advice is presented for clinicians regarding the benefits and harms of cannabis or cannabinoids for the management of chronic noncancer pain.

The association between screen time and depression seen among adolescents is potentially mediated by poor sleep.

Hormone diets have taken off on social media as the latest weight loss trend, but their scientific validity remains questionable.

The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high.

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Community-level SDOH such as household income, neighborhood walkability, and healthcare access play a greater role in predicting THA outcomes than patient race.

Engaging in physical activity concentrated within 1 to 2 days is associated with a similar reduction in mortality risk as active regular physical activity.